Patients with specific GIPR and GLP1R genetic profiles may theoretically benefit from dual-receptor agonism more robustly than single-receptor therapy, though individual response depends on many factors beyond genetics
However, its important to note that this is not a direct side effect of the medication, but rather losing an extreme amount of weight over a short period of time
In this trial, some participants will receive this combination
Information below is for educational purposes only and not medical advice
A 2023 case series published in the Journal of Clinical Psychopharmacology reported on six patients with BED treated with semaglutide, five of whom experienced substantial reductions in binge frequency and loss of control eating
New symptoms you have never experienced on semaglutide, especially at a dose you have been stable on, warrant investigation